Carboplatin: all 1,466 studies that test it

Page 8 of 15. Open to participants first (195), then studies with results posted, then the rest; newest registration first within each.

• A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04709276Phase 2
• Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 MutationsActive, not recruitingNCT04695925Phase 3
• Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung CancerStatus unknownNCT04684017Phase 2
• Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLCStatus unknownNCT04683198Phase 2
• A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT04647344Phase 1/2
• Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT04643379Phase 2
• Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT04622228Phase 2
• A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.TerminatedNCT04619433Phase 3
• Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04612751Phase 1
• Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung CancerStatus unknownNCT04592666Phase 2
• Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04592237Phase 2
• Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian CancerStatus unknownNCT04590625Phase 2
• Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLCStatus unknownNCT04586465Phase 2
• A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLCActive, not recruitingNCT04580498Phase 2
• Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal CancerCompletedNCT04572100Phase 1
• LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung CancerActive, not recruitingNCT04560972Phase 1
• Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLCStatus unknownNCT04541251Phase 2
• Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent GlioblastomaActive, not recruitingNCT04528680Phase 1/2
• Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLCCompletedNCT04507217Phase 2
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene MutationStatus unknownNCT04500717Phase 3
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLCStatus unknownNCT04500704Phase 3
• Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung CancerCompletedNCT04487756Phase 1/2
• Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).Active, not recruitingNCT04472949Phase 2
• A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid TumorsCompletedNCT04452214Phase 1
• Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBMCompletedNCT04440358Phase 1/2
• Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLCStatus unknownNCT04425135Phase 2
• Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin MonotherapyCompletedNCT04417088Phase 1/2
• Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT04387227Phase 2
• Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian CancerStatus unknownNCT04337632Phase 3
• NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBCActive, not recruitingNCT04335669Phase 3
• Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung CancerActive, not recruitingNCT04304248Phase 2
• A Phase II Study of Triple-negative Breast Cancer Brain Metastases.Status unknownNCT04303988Phase 2
• Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)Active, not recruitingNCT04296175Phase 3
• NUVOLA TRIAL Open-label Multicentre StudyStatus unknownNCT04261465Phase 2
• Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical CancerStatus unknownNCT04238988Phase 2
• Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLCStatus unknownNCT04211090Phase 2
• Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast CancerActive, not recruitingNCT04193059Phase 3
• Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaTerminatedNCT04156828Phase 1
• A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate CancerStatus unknownNCT04148885Phase 1/2
• Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04095364Phase 3
• Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast CancerActive, not recruitingNCT04083963Phase 2
• Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal CancerActive, not recruitingNCT04046575Phase 1
• Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)CompletedNCT04031703Phase 3
• A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04028050Phase 3
• A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)TerminatedNCT04022876Phase 1
• A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in ChinaActive, not recruitingNCT04015778Phase 2
• Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent IohexolActive, not recruitingNCT03997370Phase 1
• Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLCStatus unknownNCT03991403Phase 3
• Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid TumorsTerminatedNCT03968653Phase 1
• Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLCActive, not recruitingNCT03965468Phase 2
• Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingNCT03944772Phase 2
• Reduced Intensity Radio-chemotherapy for Stage IIA/B SeminomaActive, not recruitingNCT03937843Phase 2
• Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial CancerActive, not recruitingNCT03935256Phase 2
• Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial CancerActive, not recruitingNCT03932409Phase 1
• Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT03892421Phase 1/2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair DeficiencyStatus unknownNCT03876886Phase 3
• A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung CancerTerminatedNCT03866980Phase 3
• 'ADVANCE' (A Pilot Trial)Active, not recruitingNCT03858322Phase 1
• Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve FertilityTerminatedNCT03852979Phase 2
• Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast CancerStatus unknownNCT03847818Not applicable
• Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive WomenWithdrawnNCT03834571Phase 2
• A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive, not recruitingNCT03819465Phase 1
• Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung CancerTerminatedNCT03802058Phase 2
• Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLCStatus unknownNCT03799601Phase 4
• Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric CancerActive, not recruitingNCT03764553Phase 2
• Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9CompletedNCT03744026Phase 1/2
• Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.CompletedNCT03735966Phase 2
• FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/PaclitaxelCompletedNCT03723967Phase 2
• Rh-Endostatin (Endostar®) Continuous Intravenous InfusionStatus unknownNCT03706703Phase 2
• Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung CancerWithdrawnNCT03699033Phase 2
• Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal CancerStatus unknownNCT03693248Phase 3
• Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian CancerTerminatedNCT03690739Phase 3
• Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase InhibitorsStatus unknownNCT03647956Phase 2
• Comparing Palliative Radiotherapy With or Without CarboplatinTerminatedNCT03637335Phase 3
• Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.WithdrawnNCT03623776Phase 2
• Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant ChemotherapyWithdrawnNCT03607955Phase 1
• Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing SurgerySuspendedNCT03604991Phase 2/3
• The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.CompletedNCT03577704Phase 1/2
• Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownNCT03574402Phase 2
• Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingNCT03547973Phase 2
• A Study to Evaluate MEDI5752 in Subjects With Advanced Solid TumorsActive, not recruitingNCT03530397Phase 1
• Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedNCT03520686Phase 3
• Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid TumorsCompletedNCT03509012Phase 1
• Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and CarboplatinWithdrawnNCT03498222Phase 1
• Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.Status unknownNCT03467178Phase 2
• Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid TumorsCompletedNCT03430882Phase 1
• Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube CancerStatus unknownNCT03410784Phase 2
• The EPIC Trial The Elderly Patient Individualized Chemotherapy TrialStatus unknownNCT03402048Phase 3
• Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruitingNCT03385655Phase 2
• Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsWithdrawnNCT03349346Phase 1
• Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)CompletedNCT03345810Phase 2
• Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer PatientsStatus unknownNCT03321188Phase 2
• Decitabine Plus Carboplatin in the Treatment of Metastatic TNBCTerminatedNCT03295552Phase 2
• Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPCCompletedNCT03263650Phase 2
• Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor MalignanciesTerminatedNCT03209401Phase 1
• A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Phase 2/3
• A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast CancerActive, not recruitingNCT03168880Phase 3
• Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationStatus unknownNCT03151161Phase 2
• AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast CancerTerminatedNCT03147040Phase 2

← Carboplatin overview